Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 76 Days Sales Outstanding is 53.82 as of Jun. 2026, which is 9% above its 10-year median of 49.37. GuruFocus rates CHIX:BAVAC with a GF Score™ of 76/100 and a GF Value™ of kr175.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Bavarian Nordic AS ranks better than 54.93% on this metric.
The historical rank and industry rank for Bavarian Nordic AS's Days Sales Outstanding or its related term are showing as below:
CHIX:BAVAc'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 18 Med: 49.37 Max: 94.31
Current: 61.12
During the past 13 years, Bavarian Nordic AS's highest Days Sales Outstanding was 94.31. The lowest was 18.00. And the median was 49.37.
CHIX:BAVAc's Days Sales Outstanding is ranked better than 54.93% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs CHIX:BAVAc: 61.12
Bavarian Nordic AS's Days Sales Outstanding
declined
from Jun. 2025 (57.22) to Jun. 2026 (53.82).
Bavarian Nordic AS (CHIX:BAVAc) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Bavarian Nordic AS Days Sales Outstanding Related Terms
Bavarian Nordic AS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Days Sales Outstanding falls into.
Bavarian Nordic AS Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a Days Sales Outstanding of 53.82 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bavarian Nordic AS and its competitors. This is near median its historical median of 49.37. Over the past decade, Bavarian Nordic AS's Days Sales Outstanding has ranged from 18.00 to 94.31. According to the industry distribution chart, Bavarian Nordic AS ranks #379 out of 841 companies in the Biotechnology industry, placing it in the top 45.1%.
Is Bavarian Nordic AS's Days Sales Outstanding too high?
Bavarian Nordic AS's current Days Sales Outstanding of 53.82 is near median its 10-year median of 49.37. Over the past 10 years, this metric has ranged from a low of 18.00 to a high of 94.31. The Biotechnology industry median Days Sales Outstanding is 68.98. Bavarian Nordic AS's value of 53.82 is 22% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #379 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bavarian Nordic AS has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #379 out of 841 companies for Days Sales Outstanding. This puts Bavarian Nordic AS in the upper half of its industry. The industry median Days Sales Outstanding is 68.98. Bavarian Nordic AS's value of 53.82 is 22% below this benchmark. Historically, Bavarian Nordic AS's own Days Sales Outstanding has ranged from 18.00 to 94.31 over the past decade. While the company's 10-year median is 49.37 vs. the industry median of 68.98, Bavarian Nordic AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current Days Sales Outstanding of 53.82 is 22% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Days Sales Outstanding is 53.82, which is near median its own 10-year median of 49.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr175.53, compared to a current price of kr216.80 — trading 23.5% above its estimated fair value. The current Days Sales Outstanding is 53.82, which is near median its 10-year median of 49.37 and 22% below the Biotechnology industry median of 68.98. Bavarian Nordic AS's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Days Sales Outstanding is 53.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr216.80 is trading 23.5% above its estimated GF Value™ of kr175.53.
GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.
Key valuation signals for CHIX:BAVAC:
Days Sales Outstanding: 53.82 (near median its 10-year median of 49.37)
GF Value™: kr175.53 vs. price of kr216.80 (23.5% above fair value)
Industry Position: 22% below the Biotechnology median (#379 of 841)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
76GF Score
Get the complete analysis for CHIX:BAVAC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
